AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The formulation is backed by over 80 clinical trials and 200 scientific publications
SOMA Color Mind is designed to simplify and accelerate color setup directly on the printing press
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The move is expected to be crucial during health crises
Subscribe To Our Newsletter & Stay Updated